KLHDC1: A Potential Drug Target and Biomarker (G122773)

Target Name: KLHDC1

NCBI ID: G122773

KLHDC1

KLHDC1: A Potential Drug Target and Biomarker

KLHDC1, also known as Kelch domain-containing protein 1, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique protein structure and subcellular localization make it an attractive target for small molecules and antibodies.

KLHDC1 is a 21-kDa protein that is expressed in various tissues and cells in the body. It is characterized by a long N-terminus that contains a Kelch domain, a N-terminal transmembrane domain, and a C-terminus that contains a unique farnesylated cysteine residue. The Kelch domain is a small protein domain that is composed of four amino acids and is known for its ability to form a stable complex with various ligands, including small molecules and drugs.

KLHDC1 has been shown to play a role in various cellular processes, including cell signaling, cell division, and tissue repair. It is involved in the regulation of cell adhesion, cell migration, and the formation of tight junctions, which are important for tissue structure and function. KLHDC1 has also been shown to play a role in the regulation of inflammation and immune responses.

As a potential drug target, KLHDC1 is of interest for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. KLHDC1 has been shown to be involved in the regulation of cancer cell growth, and has been used as a biomarker for the diagnosis and prognosis of various types of cancer. Additionally, KLHDC1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

As a potential biomarker, KLHDC1 has been shown to be involved in various physiological processes, including cell signaling, cell division, and tissue repair. It has been shown to be involved in the regulation of cell adhesion, cell migration, and the formation of tight junctions. Additionally, KLHDC1 has been shown to play a role in the regulation of inflammation and immune responses.

KLHDC1 has been shown to be involved in the regulation of various cellular processes in the body, making it an attractive target for small molecules and antibodies. Studies have shown that small molecules, such as inhibitors of the Kelch domain, can inhibit the activity of KLHDC1 and prevent it from functioning as a drug target or biomarker. Additionally, antibodies that recognize and target specific residues on KLHDC1 have been shown to be effective in inhibiting its activity and reducing the risk of certain diseases.

In conclusion, KLHDC1 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique protein structure and subcellular localization make it an attractive target for small molecules and antibodies. Further research is needed to fully understand the role of KLHDC1 in various cellular processes and its potential as a drug target and biomarker.

Protein Name: Kelch Domain Containing 1

Functions: Substrate-recognition component of a Cul5-RING (CRL5) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:32200094). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:32200094). The CRL5(KLHDC1) complex mediates ubiquitination and degradation of truncated SELENOS selenoprotein produced by failed UGA/Sec decoding, which ends with a glycine (PubMed:32200094)

The "KLHDC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHDC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets